Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report report published on Thursday. The brokerage issued a sell rating on the biotechnology company’s stock.

Other research analysts also recently issued research reports about the company. HC Wainwright reissued a “buy” rating and issued a $60.00 target price on shares of Aptose Biosciences in a report on Wednesday, February 12th. Alliance Global Partners upgraded shares of Aptose Biosciences to a “strong-buy” rating in a research note on Thursday, February 27th. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Aptose Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $112.00.

Aptose Biosciences Price Performance

NASDAQ APTO opened at $3.32 on Thursday. The stock has a market capitalization of $7.11 million, a price-to-earnings ratio of -1.12 and a beta of 1.14. Aptose Biosciences has a 1-year low of $2.39 and a 1-year high of $51.61. The business’s fifty day moving average price is $4.57 and its 200-day moving average price is $7.52.

Institutional Trading of Aptose Biosciences

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp lifted its stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 75.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 703,384 shares of the biotechnology company’s stock after acquiring an additional 301,634 shares during the quarter. Sigma Planning Corp owned approximately 1.17% of Aptose Biosciences worth $158,000 at the end of the most recent reporting period. 26.62% of the stock is owned by hedge funds and other institutional investors.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.